ANGE-S003

ANGE-S003 is an investigational human neural stem cell (h-NSC) therapy being developed for the treatment of Parkinson's disease. Developed by Shanghai Angecon Biotechnology in collaboration with the Second Affiliated Hospital of Soochow University, the therapy is unique for its intranasal route of administration, which aims to bypass the blood-brain barrier to deliver cells directly to the central nervous system. In clinical trials, the therapy has demonstrated feasibility and safety, with functional improvements observed in patients with advanced Parkinson's disease. The mechanism involves the potential for neural stem cells to differentiate, provide neurotrophic support, or modulate the microenvironment to mitigate dopaminergic neuron loss.

Other names

human neural stem cellsh-NSChuman neural stem cell-Second Affiliated Hospital of Soochow University-Parkinson's disease